Daniel Bar1, Ofer Lavie2, Nili Stein3, Ido Feferkorn1, Ayelet Shai4. 1. Gynecology-Oncology Unit, Department of Obstetrics and Gynecology, Carmel Lady Davis Medical Center, Haifa, Israel. 2. Gynecology-Oncology Unit, Department of Obstetrics and Gynecology, Carmel Lady Davis Medical Center, Haifa, Israel; Bruce Rappaport Faculty of Medicine, Technion-Israeli Institute of Technology, Haifa, Israel. 3. Department of Community Medicine and Epidemiology, Carmel Lady Davis Medical Center, Haifa, Israel. 4. Department of Oncology, Galilee Medical Center, Nahariyya, Israel; Faculty of Medicine, Bar Illan University, Zafed, Israel. Electronic address: ayelets@gmc.gov.il.
Abstract
BACKGROUND: Diabetes mellitus is associated with an increased risk of recurrence in patients with ovarian cancer. Retrospective studies suggested that the use of statins, metformin and beta blockers is associated with improved prognosis in these patients. Patients with diabetes often suffer from hypertension and are usually treated concomitantly by several classes of drugs. Our aim was to assess the independent contribution of diabetes mellitus and hypertension and of the use of aspirin, statins, metformin and beta blockers on the risk of ovarian cancer recurrence and mortality. METHODS: Files of ovarian cancer patients treated between 2000 and 2012 were retrospectively reviewed. Data regarding disease characteristics, presence of diabetes mellitus and hypertension, recurrence and death were extracted. The use of drugs was assessed using the Clalit Health Services (CHS) pharmacy records. RESULTS: 143 patients treated by debulking surgery and platinum based chemotherapy were included. Median age was 62.5, 22 (15.4%) had diabetes mellitus, 61 (42.7%) had chronic hypertension. Statins were used by 43 (30%) patients, 31 (21.7%) used aspirin, 25 (17.5%) used beta blockers and 12 (8.4%) used metformin. In multivariate analysis diabetes mellitus was associated with a shorter recurrence free survival (RFS) and the use of aspirin and metformin was associated with a prolonged RFS in this cohort. Overall survival (OS) was longer in patients using aspirin and shorter in patients with hypertension. CONCLUSIONS: Our data suggests that metabolic comorbidities and commonly used drugs are associated with the prognosis of patients with ovarian cancer. Additional trials are needed to confirm these observations and test therapeutic interventions.
BACKGROUND:Diabetes mellitus is associated with an increased risk of recurrence in patients with ovarian cancer. Retrospective studies suggested that the use of statins, metformin and beta blockers is associated with improved prognosis in these patients. Patients with diabetes often suffer from hypertension and are usually treated concomitantly by several classes of drugs. Our aim was to assess the independent contribution of diabetes mellitus and hypertension and of the use of aspirin, statins, metformin and beta blockers on the risk of ovarian cancer recurrence and mortality. METHODS: Files of ovarian cancerpatients treated between 2000 and 2012 were retrospectively reviewed. Data regarding disease characteristics, presence of diabetes mellitus and hypertension, recurrence and death were extracted. The use of drugs was assessed using the Clalit Health Services (CHS) pharmacy records. RESULTS: 143 patients treated by debulking surgery and platinum based chemotherapy were included. Median age was 62.5, 22 (15.4%) had diabetes mellitus, 61 (42.7%) had chronic hypertension. Statins were used by 43 (30%) patients, 31 (21.7%) used aspirin, 25 (17.5%) used beta blockers and 12 (8.4%) used metformin. In multivariate analysis diabetes mellitus was associated with a shorter recurrence free survival (RFS) and the use of aspirin and metformin was associated with a prolonged RFS in this cohort. Overall survival (OS) was longer in patients using aspirin and shorter in patients with hypertension. CONCLUSIONS: Our data suggests that metabolic comorbidities and commonly used drugs are associated with the prognosis of patients with ovarian cancer. Additional trials are needed to confirm these observations and test therapeutic interventions.
Authors: Melissa A Merritt; Megan S Rice; Mollie E Barnard; Susan E Hankinson; Ursula A Matulonis; Elizabeth M Poole; Shelley S Tworoger Journal: Lancet Oncol Date: 2018-07-18 Impact factor: 41.316
Authors: Eerik E E Santala; Miia Artama; Eero Pukkala; Kala Visvanathan; Synnöve Staff; Teemu J Murtola Journal: Cancers (Basel) Date: 2021-04-26 Impact factor: 6.639
Authors: Elina Urpilainen; Mikko Marttila; Ari Hautakoski; Martti Arffman; Reijo Sund; Pirjo Ilanne-Parikka; Reetta Arima; Jenni Kangaskokko; Ulla Puistola; Marianne Hinkula; Esa Läärä Journal: BMC Cancer Date: 2018-07-28 Impact factor: 4.430
Authors: Peter C Elwood; Janet E Pickering; Gareth Morgan; Julieta Galante; Alison L Weightman; Delyth Morris; Marcus Longley; Malcolm Mason; Richard Adams; Sunil Dolwani; John Chia W K; Angel Lanas Journal: PLoS One Date: 2018-09-25 Impact factor: 3.240